Regulation of somatostatin receptor 2 in the context of antidepressant treatment response in chronic mild stress in rat

Abstract

RationaleThe role of somatostatin and its receptors for the stress-related neuropsychiatric disorders has been widely raised. Recently, we have also demonstrated the involvement of somatostatin receptor type 2-sst2R and dopamine receptor type 2-D2R in stress.ObjectiveIn this context, we decided to find if these receptors are involved in response to antidepressant treatment in animal model of depression—chronic mild stress (CMS).MethodsHere, we report data obtained following 7-week CMS procedure. The specific binding of [125I]Tyr3-Octreotide to sst2R and [3H]Domperidone to D2R was measured in the rat brain, using autoradiography. Additionally, the level of dopamine and metabolites was measured in the rat brain.ResultsIn the final baseline test after 7 weeks of stress, the reduced consumption of sucrose solution was observed (controls vs the stressed animals (6.25 0.16 vs. 10.39 0.41; p < 0.05). Imipramine was administered for the next 5 weeks, and it reversed anhedonia in majority of animals (imipramine-reactive); however, in some animals, it did not (imipramine-non-reactive). Two-way repeated measures ANOVA revealed significant effects of stress and treatment and time interaction [F(16, 168) = 3.72; p < 0.0001], n = 10 per groups. We observed decreased binding of [125I]Tyr3-Octreotide in most of rat brain regions in imipramine non-reactive groups of animals. The decrease of D2R after stress in striatum and nucleus accumbens and no effect of imipramine were observed.In the striatum and prefrontal cortex, the significant role of stress and imipramine in dopamine levels was observed.ConclusionsThe results obtained in binding assays, together with dopamine level, indicate the involvement of sst2R receptors for reaction to antidepressant treatment. Besides, the stress context itself changes the effect of antidepressant drug.

Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions

“…Drugs that act as selective SST2 receptor agonists, such as L-779,976, have never been tested in clinical trials. Thus, given that SST levels were reported to be lower in the brain of MDD patients and stressed rodents ( Frye et al, 2003 ; Tripp et al, 2011 ), which can be normalized by monoaminergic drugs ( Faron-Gorecka et al, 2016 , 2018 ), and preclinical evidence that SST induces antidepressant-like effects, clinical studies testing the antidepressant potential of selective SST2 receptor analogs with longer half-life merit additional attention.…”

Beneficial effects of octreotide in alcohol-induced neuropathic pain. Role of H 2S, BDNF, TNF-α and Nrf2

“…In this study, treatment with somatostatin analogue, i.e., octreotide, led to significant improvement in neuropathic pain manifestations. There have been studies showing that apart from endocrinological effects, octreotide produces a number of beneficial effects in different disease states, including ischemia-reperfusion injury 27 , depression 28 , dementia 29 . Administration of octreotide in the ventrolateral orbital cortex has been shown to produce antinociceptive effects in formalin-induced nociceptive behavior in rats 12 .…”

Somatostatin and Somatostatin-Containing Interneurons—From Plasticity to Pathology

“…Investigations of the role of SOM receptors in the hippocampus of mice revealed that SSTR2 agonists selectively produced anxiolytic-like behaviors, whereas both SSTR2 and SSTR4 agonists had antidepressant-like effects. Moreover, SSTR2 receptors were sensitive to antidepressant treatment—their changed activity was observed during imipramine administration in the chronic mild stress model of depression [ 117 ]. In SST2KO mice, high corticosterone levels and anxiety were found and depressive-like behaviors were observed in both SST2KO and SST4KO strains [ 116 ].…”